Epitalon: telomerase, the pineal gland and ageing research

Few research peptides carry claims as large as Epitalon's. It is often said to switch on telomerase, lengthen telomeres and extend lifespan. Each of those phrases refers to a different kind of finding, obtained in a different experimental system, and they are frequently run together. This article traces where the claims come from and sets out, as precisely as the literature allows, what has and has not been shown.

Origins: from a pineal extract to a tetrapeptide

Epitalon, also written Epithalon or Epithalone, is a tetrapeptide with the sequence alanine–glutamic acid–aspartic acid–glycine (AEDG). It was synthesised on the basis of the amino acid composition of epithalamin, an extract of bovine pineal gland^[1]. Researchers working with it have described epithalamin as a pharmacopoeia drug in Russia and Epitalon as its synthetic analogue^[2].

Much of the research has come from a single network centred on the St Petersburg Institute of Bioregulation and Gerontology, with Vladimir Khavinson as a central author, working with collaborators in Russia and elsewhere. A 2025 review noted that, after about 25 years of in vitro, in vivo and in silico work, it remains uncertain whether the mechanisms described so far fully explain the peptide's reported effects, and that physico-chemical and structural studies of the peptide are still limited^[1].

A map of the claims

Telomerase and telomere length in cells

Telomeres are protective caps at the ends of chromosomes that shorten with each cell division. Telomerase is the enzyme that can rebuild them. Most adult human somatic cells produce little of it, and shortened telomeres are one of many cellular markers associated with ageing.

The foundational report, published in 2003, described adding Epitalon to cultures of telomerase-negative human fetal fibroblasts. The authors reported expression of telomerase's catalytic subunit, telomerase enzyme activity and telomere elongation. They suggested this indicated the possibility of prolonging the life span of a cell population and of the whole organism^[3]. That final step is an extrapolation, not a result.

The most substantial independent follow-up was published in 2025. Researchers treated normal human epithelial cells and fibroblasts, along with two breast cancer cell lines. In normal cells, Epitalon produced dose-dependent telomere lengthening, accompanied by increased hTERT (telomerase) mRNA expression and telomerase activity. In the cancer cell lines, telomeres also lengthened, but largely through a different route: alternative lengthening of telomeres (ALT), a telomerase-independent mechanism^[4].

Lifespan in animals

The lifespan evidence comes from invertebrate and rodent studies, mostly by the originating research group.

In fruit flies (Drosophila melanogaster), adding Epitalon to the culture medium during development increased adult lifespan by 11% to 16%. The effect was seen across a wide range of very low concentrations and did not depend on dose^[5].

The most detailed mammalian study followed female mice treated from three months of age until natural death, with 54 animals per group. Epitalon did not change food intake, body weight or mean lifespan. It did increase the lifespan of the longest-lived 10% of animals by 13.3% and maximum lifespan by 12.3%. It also slowed the age-related decline in oestrous function and reduced chromosome aberrations in bone marrow cells. Total spontaneous tumour incidence was unchanged, although leukaemia was less frequent^[6].

The absence of an effect on mean lifespan is important and is often omitted when the study is summarised. An increase confined to the longest-lived animals, in a single group of 54 mice, is a far weaker result than a general extension of lifespan.

Tumour models

The same group reported that Epitalon slowed ageing markers and suppressed breast adenocarcinoma development in mice genetically engineered to overexpress HER-2/neu^[9]. In rats given a chemical that induces colon cancer, Epitalon reduced the number of colon tumours per animal when given throughout the experiment or during carcinogen exposure. It had no significant effect when started only after exposure ended^[7].

These are carefully described experiments in established models. They come from one research network, however, and the in vitro finding of ALT-mediated telomere lengthening in cancer cells^[4] means that the relationship between Epitalon and cancer biology warrants independent study rather than assumption.

The pineal gland and melatonin

A distinct line of work concerns the pineal gland, which produces the night-time hormone melatonin. In old rhesus monkeys aged 20 to 27, Epitalon increased night-time melatonin, lowered basal glucose and insulin, and improved the response to a glucose load. It did not affect young animals^[2].

A Russian-language report described similar effects in people: in elderly individuals with reduced pineal function, epithalamin and Epitalon were reported to increase night-time melatonin levels. The authors recommended the preparations for clinical geriatric practice^[8]. The abstract gives limited detail on study design, participant numbers or controls, so this finding is difficult to evaluate independently.

Gene regulation: an epigenetic hypothesis

More recent work has proposed that Epitalon acts on gene expression. In human gingival mesenchymal stem cells, it increased markers of neuronal differentiation, with mRNA levels 1.6 to 1.8 times higher than controls. Molecular modelling suggested that the peptide may bind preferentially to particular histone proteins^[10]. Modelling of this kind generates a hypothesis about mechanism. It does not demonstrate that binding occurs in living cells.

A 2025 cell study found that Epitalon restored delayed wound healing in human retinal pigment epithelial cells exposed to high glucose, which the authors attributed to antioxidant effects and reduced fibrosis-related changes^[11].

Human evidence

Among the sources reviewed for this article, human data are limited to the Russian-language melatonin report described above. We did not identify controlled clinical trials of Epitalon measuring telomere length, biological ageing, disease incidence or lifespan in people. Claims that Epitalon slows human ageing therefore rest on extrapolation from cell culture and animal studies.

Reading the programme as a whole

• Concentration. Most studies come from one research network. Several are brief reports, and some are published only in Russian.
• Independent replication. The 2025 telomere study is valuable precisely because it is independent, and it adds an important caveat about cancer cells.
• Scale. Key animal studies use modest group sizes, and single experiments are rarely repeated.
• Extrapolation. Conclusions about organismal ageing are frequently drawn from cellular markers.

Summary

Epitalon is a synthetic tetrapeptide with a long research history. Cell studies, including one independent replication, show telomerase activation and telomere lengthening in culture. Animal studies report longer survival in flies and among the longest-lived mice, but no change in average mouse lifespan, alongside effects in several tumour models. Work in old monkeys and a limited human report point to effects on melatonin. Controlled human evidence on ageing is absent. The most accurate summary is that Epitalon is an interesting subject of ageing research, not a demonstrated means of slowing human ageing.